The merger with Eos SENOLYTIX is the only near-term catalyst, but it is highly dilutive to current shareholders. Monitor for shareholder vote and merger close; the stock is likely to trade on merger arbitrage dynamics rather than fundamentals. The going concern warning and minimal cash runway add downside risk if the merger fails.
Price Chart
Executive Summary
Pulmatrix reported Q2 2026 financial results with minimal revenue, a net loss of $1.0M, and a cash burn that reduced its cash position to $2.2M. The primary focus is the pending reverse merger with Eos SENOLYTIX, expected to close in Q3 2026, which will leave current Pulmatrix shareholders with only ~6% of the combined entity. The press release also notes a Form S-4 filing for the merger and a strategy to out-license its clinical assets, but the company's going concern warning and the dilutive nature of the merger dominate the outlook.
Key Financial Metrics
Key Facts
- Cash and cash equivalents fell to $2.2M as of June 30, 2026, from $4.1M at year-end 2025.
- Net loss attributable to common stockholders was $1.05M for Q2 2026, compared to $1.55M in Q2 2025.
- The company has a going concern warning, stating cash is sufficient only through the anticipated merger close.
- The proposed merger with Eos SENOLYTIX is expected to close in Q3 2026, with current Pulmatrix shareholders owning ~6% of the combined company.
- A Form S-4 has been filed for the merger, and a $1.0M private placement of Series B Convertible Preferred Stock was completed in March 2026.
- All clinical development is on hold as the company seeks to out-license or monetize its assets.
Financial Impact
Cash burn of ~$1.9M in H1 2026; net loss of $2.2M for the six months ended June 30, 2026.
Risk Factors
- Merger fails to close, leaving Pulmatrix with insufficient cash to continue operations.
- Extreme dilution for current shareholders if merger completes (current holders to own ~6% of combined entity).
- Inability to out-license clinical assets, leaving no value from the existing pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850250 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | S-4/A | $1.40 $1.45 | ▼ −3.58% | ▼ −4.70% | $1.57 (−12.54%) |
Aug 13, 2026 7w ago | 8-K | $1.51 $1.50 | ▼ −0.66% | ▲ +1.30% | $1.57 (+3.97%) |
Aug 13, 2026 7w ago | Press Release | $1.51 $1.50 | ▲ +0.66% | ▼ −1.30% | $1.57 (−3.97%) |
Aug 7, 2026 7w ago | S-3/A | $1.57 $1.56 | ▲ +0.64% | ▲ +0.59% | $1.57 (−0.00%) |
Jun 16, 2026 15w ago | 10-K/A | $1.50 $1.53 | ▲ +2.00% | ▲ +3.04% | $1.57 (+4.67%) |
Jun 5, 2026 17w ago | 425 | $1.33 $1.40 | ▲ +5.26% | ▲ +4.69% | $1.57 (+18.05%) |
Jun 4, 2026 17w ago | S-3 | $1.32 $1.38 | ▼ −4.55% | ▼ −7.10% | $1.57 (−18.94%) |
May 15, 2026 20w ago | 8-K | $1.25 $1.34 | ▲ +7.20% | ▲ +6.24% | $1.57 (+25.60%) |
Apr 21, 2026 23w ago | 8-K | $1.38 $1.28 | ▼ −7.25% | ▼ −8.33% | $1.57 (+13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access